Sustained a primary fragility fracture (hip/femur, pelvis, clinical spine, humerus, wrist) in the last 12 months
Participant must self-identify a regular primary care provider (PCP)
Participant must provide a mailing address
Participant must plan to remain geographically proximate (able to travel if necessary) to the site from which they are recruited over the next several months
You may not be if
Exposure to the following medications in the prior 12 months;
Actonel or Atelvia (risedronate)
Fosamax or Binosto (alendronate)
Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate)
Boniva or Bondronat (ibandronate)
Aredia (pamidronate)
Prolia (denosumab)
Evenity (romozosumab)
Tymlos (abaloparatide)
Forteo (teriparatide)
Natpara (parathyroid hormone)
Evista (raloxifene)
Duavee (bazedoxifene-conjugated estrogen)
Miacalcin (calcitonin)
Diagnosis of the following medical conditions;
CKD stage 4 or 5 or on dialysis
Multiple myeloma
Addison's disease
Adrenal insufficiency
Enrolled hospice care
Solid organ transplant, or expecting a solid organ transplant
Bone marrow transplant
History of metabolic bone disease (except osteoporosis) such as Paget's disease, osteomalacia, osteogenesis imperfecta, or Cushing's disease
Fractures resulting from severe trauma (e.g. motor vehicle accidents, a fall from 2 feet or higher elevation)
Pathologic fractures secondary to malignancy or infection
Scheduled appointment with a bone health specialist
Participant unable to consent on their own (cognitive impairment, dementia, etc.)
Currently enrolled in another research study that requires taking medication
Clareo Health | RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
